1. Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing
- Author
-
Jeeyun Lee, Jinah Chu, Seung Tae Kim, Won Ki Kang, Heewon Han, Binnari Kim, Insuk Sohn, Sang Yun Ha, Kyoung-Mee Kim, and Sangjoon Choi
- Subjects
0301 basic medicine ,medicine.diagnostic_test ,Receiver operating characteristic ,Genetic heterogeneity ,Biology ,Molecular biology ,DNA sequencing ,Pathology and Forensic Medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Biopsy ,Gene expression ,Gene duplication ,medicine ,Molecular Medicine ,Immunohistochemistry ,skin and connective tissue diseases ,Receptor ,neoplasms - Abstract
Intratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) is common in gastric cancer (GC). However, a direct comparison between the results of HER2 immunohistochemistry (IHC) and next-generation sequencing (NGS)–based cancer panel tests has not been explored in GC. We aimed to determine optimal thresholds of HER2 overexpression to be detected by NGS with the data of 168 metastatic GC cases with known expression levels of HER2 by IHC and the copy number alteration of ERBB2 obtained by NGS test by applying tumor heterogeneity index (THI) and receiver operating characteristic curve. GC tissues were obtained via biopsy (N = 103) and gastrectomy (N = 65). HER2 3+ by IHC was observed in 27 cases (16%), and 14 of 27 HER2 IHC 3+ cases (52%) showed intratumoral heterogeneity (
- Published
- 2019
- Full Text
- View/download PDF